Review Article | Published:

Vitamin D status in irritable bowel syndrome and the impact of supplementation on symptoms: what do we know and what do we need to know?

European Journal of Clinical Nutritionvolume 72pages13581363 (2018) | Download Citation

Abstract

Background

Low vitamin D status is associated with risk of colorectal cancer and has been implicated in inflammatory bowel disease. Irritable bowel syndrome (IBS) is a chronic, relapsing, functional bowel disorder. A nascent literature suggests a role for vitamin D in IBS, but this has not been collated or critiqued. To date, seven studies have been published: four observational studies and three randomised controlled trials (RCTs). All observational studies reported that a substantial proportion of the IBS population was vitamin D deficient. Two intervention studies reported improvement in IBS symptom severity scores and quality of life (QoL) with vitamin D supplementation.

There are limited data around the role of vitamin D in IBS.

Conclusions

The available evidence suggests that low vitamin D status is common among the IBS population and merits assessment and rectification for general health reasons alone. An inverse correlation between serum vitamin D and IBS symptom severity is suggested and vitamin D interventions may benefit symptoms. However, the available RCTs do not provide strong, generalisable evidence; larger and adequately powered interventions are needed to establish a case for therapeutic application of vitamin D in IBS.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Kulie T, Groff A, Redmer J, Hounshell J, Schrager S. Vitamin D: an evidence-based review. J Am Board Fam Med. 2009;22:698.

  2. 2.

    Fraser DR. Vitamin D. Lancet. 1995;345:104–7.

  3. 3.

    Holick MF, Holick MF. Vitamin D [electronic resource]: physiology, molecular biology, and clinical applications. 2nd ed. Totowa, NJ: Humana; 2010.

  4. 4.

    Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. Obstet. 2011;66:356–7.

  5. 5.

    Khayyat Y, Attar S. Vitamin D deficiency in patients with irritable bowel syndrome: does it exist? Oman Med J. 2015;30:115.

  6. 6.

    Nwosu BU, Maranda L, Candela N. Vitamin D status in pediatric irritable bowel syndrome. PLoS ONE. 2017;12:e0172183.

  7. 7.

    NICE. Vitamin D: increasing supplement use in at-risk groups. London, UK: NICE; 2014. https://www.nice.org.uk/guidance/ph56

  8. 8.

    Buttriss JL. Vitamin D: sunshine vs. diet vs. pills. Nutr Bull. 2015;40:279–85.

  9. 9.

    Del Pinto R, Pietropaoli D, Chandar A, Ferri C, Cominelli F. Association between inflammatory bowel disease and vitamin D deficiency: a systematic review and meta-analysis. Dig Liver Dis. 2016;48:E161.

  10. 10.

    Zhang X, Giovannucci E. Calcium, vitamin D and colorectal cancer chemoprevention. Best Pract. 2011;25:485–94.

  11. 11.

    Touvier M, Chan DS, Lau R, Aune D, Vieira R, Greenwood DC, et al. Meta-analyses of vitamin D intake, 25-hydroxyvitamin D status, vitamin D receptor polymorphisms, and colorectal cancer risk. Cancer Epidemiology, Biomarkers & Prevention. 2011;20:1003–1016.

  12. 12.

    Dulai PS, Singh S, Marquez E, Khera R, Prokop LJ, Limburg PJ, et al. Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: systematic review and network meta-analysis. BMJ 2016;355.

  13. 13.

    Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130:1480–91.

  14. 14.

    Soubieres A, Wilson P, Poullis A, Wilkins J, Rance M. Burden of irritable bowel syndrome in an increasingly cost-aware National Health Service. Frontline Gastroenterol. 2015;6:246.

  15. 15.

    Lee B, Bak Y. Irritable bowel syndrome, gut microbiota and probiotics. J Neurogastroenterol Motil 2011;17:252–66.

  16. 16.

    Boersma K, Ljótsson B, Edebol-Carlman H, Schrooten M, Linton SJ, Brummer RJ. Exposure-based cognitive behavioral therapy for irritable bowel syndrome. A single-case experimental design across 13 subjects. Cogn Behav Ther. 2016;45:415–30.

  17. 17.

    Canavan C, West J, Card T. Review article: the economic impact of the irritable bowel syndrome. Aliment Pharmacol Ther J. 2014;40:1023–34.

  18. 18.

    Wilkins T, Pepitone C, Alex B, Schade RR. Diagnosis and management of IBS in adults. Am Fam Physician. 2012;86:419.

  19. 19.

    Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology. 2006;130:1377–90.

  20. 20.

    Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. Br Med J. 1978;2:653.

  21. 21.

    Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology. 2000;119:654–60.

  22. 22.

    Sprake EF, Grant VA, Corfe BM. Vitamin D3 as a novel treatment for irritable bowel syndrome: single case leads to critical analysis of patient-centred data. BMJ Case Rep. 2012;2012.

  23. 23.

    Abbasnezhad A, Amani R, Hajiani E, Alavinejad P, Cheraghian B, Ghadiri A. Effect of vitamin D on gastrointestinal symptoms and health-related quality of life in irritable bowel syndrome patients: a randomized double-blind clinical trial. Neurogastroenterol Motil. 2016;28:1533–44.

  24. 24.

    Jalili M, Hekmatdoost A, Vahedi H, Poustchi H, Khademi B, Saadi M, et al. Co-Administration of soy isoflavones and vitamin D in management of irritable bowel disease. PLoS ONE. 2016;11.

  25. 25.

    Tazzyman S, Richards N, Trueman AR, Evans AL, Grant VA, Garaiova I, et al. Vitamin D associates with improved quality of life in participants with irritable bowel syndrome: outcomes from a pilot trial. BMJ Open Gastroenterol. 2015;2:e000052.

  26. 26.

    Al-Ajlan AS. Screening of coeliac disease in undetected adults and patients diagnosed with irritable bowel syndrome in Riyadh, Saudi Arabia. Saudi J Biol Sci. 2016;23:462–6.

  27. 27.

    Al-Daghri NM. Vitamin D in Saudi Arabia: prevalence, distribution and disease associations. J Steroid Biochem Mol Biol. 2016;175:102–7.

  28. 28.

    Yarandi S, Christie J. The prevalence of vitamin D deficiency in patients with irritable bowel syndrome. Am J Gastroenterol. 2013;108:S565.

  29. 29.

    Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol. 1997;11:395–402.

  30. 30.

    Bengtsson M, Hammar O, Ohlsson B, Mandl T. Evaluation of gastrointestinal symptoms in different patient groups using the visual analogue scale for irritable bowel syndrome (VAS-IBS). BMC Gastroenterol. 2011;11.

  31. 31.

    Rahnavard Z, Eybpoosh S, Rezaei Homami M, Aghaei Meybodi HR, Azemati B, Heshmat R, et al. Vitamin D deficiency in healthy male population: results of the Iranian multi-center osteoporosis study. Iran J Public Health. 2010;39:45–52.

  32. 32.

    Kazemi A, Sharifi F, Jafari N, Mousavinasab N. High prevalence of vitamin D deficiency among pregnant women and their newborns in an Iranian population. J Women'S Health. 2009;18:835–9.

  33. 33.

    Ahmad S, Mohammad Hassan L, Zahra N, Sedighe Akhavan K, Malihe G, Mehrdad S. Study to evaluate two dosage regimens of vitamin D through an academic year in middle school girls: a randomized trial. Acta Med Iran. 2011;49:780–3.

  34. 34.

    Meybodi H, Bagheri A, Soltani A, Tehrani MM, Khashayar P, Heshmat R, et al. Effect of high dose versus conventional vitamin D supplement on serum 25(OH)D levels in women with low bone mass. Osteoporos Int. 2010;21:S744.

Download references

Author contributions

C.E.W. undertook the searches, collated literature and wrote the first draft. E.A.W. co-conceived the study, reviewed and edited all drafts. B.M.C. co-conceived the study, undertook the searches, collated the literature and edited all drafts. All authors agreed the final version of the manuscript.

Funding

This work was jointly supported by BetterYou Ltd and The University of Sheffield.

Author information

Affiliations

  1. Molecular Gastroenterology Research Group, Academic Unit of Surgical Oncology, Department of Oncology & Metabolism, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, UK

    • Claire E. Williams
    •  & Bernard M. Corfe
  2. Department of Oncology & Metabolism, Human Nutrition Unit, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, UK

    • Elizabeth A. Williams
  3. Insigneo Institute for In Silico Medicine, The University of Sheffield, Sheffield, S10 2RX, UK

    • Bernard M. Corfe

Authors

  1. Search for Claire E. Williams in:

  2. Search for Elizabeth A. Williams in:

  3. Search for Bernard M. Corfe in:

Conflict of interest

The authors authored two of the systematically reviewed papers. BetterYou markets vitamin D supplements.

Corresponding author

Correspondence to Bernard M. Corfe.

Electronic supplementary material

About this article

Publication history

Received

Revised

Accepted

Published

DOI

https://doi.org/10.1038/s41430-017-0064-z

Further reading